Sanofi reported strong growth and successful new product launches, with significant gains in Dupixent and vaccines. Strategic acquisitions and sustainability leadership were also positive. However, challenges in the flu market and mixed results for itepekimab in COPD, along with potential future tariff impacts, present areas of concern.

Company Guidance -

Q3 2025

During the Q2 2025 conference call, Sanofi refined its 2025 sales guidance to a high single-digit percentage growth at constant exchange rates, highlighting strong quarterly performance with double-digit sales growth driven by new launches and key products such as Dupixent, which saw sales rise by 21% to €3.8 billion. The company reported a 10.1% increase in net sales at constant exchange rates, with gross margin improving by 1.5 points. The vaccine business also grew by 10.3%, supported by the expansion of Beyfortus and the late flu season in the Northern Hemisphere. The launch of new products contributed nearly €1 billion in sales during Q2, accounting for 10% of total sales. Sanofi also emphasized ongoing strategic investments in R&D, which saw a 17.7% increase, and the successful completion of the Blueprint Medicines acquisition, enhancing its position in rare diseases. Despite challenges, the company maintained its full-year EPS guidance of low double-digit growth at constant exchange rates.

Strong Sales Growth

Sanofi delivered double-digit sales growth with net sales increasing by 10.1% at constant exchange rate in Q2 2025.

Successful New Launches

New launches generated close to EUR 1 billion in sales, contributing to 10% of total sales and 25% of growth in Q2.

Dupixent Performance

Dupixent sales reached EUR 3.8 billion, up 21% in Q2, with significant contributions from new indications like COPD.

Vaccine Business Growth

Vaccine sales increased by 10.3% in Q2, driven by Beyfortus expansion and flu season performance.

Strategic Acquisitions

Completed acquisitions of Blueprint Medicines and Vicebio, strengthening positions in rare diseases and vaccines.

Sustainability Leadership

Sanofi ranked as the world's 10th most sustainable company by TIME and #1 in pharma and biotech.

Improved Financial Performance

Gross margin improved by 1.5 percentage points, and business EPS was EUR 1.59, up 8.3%.

Sanofi (FR:SAN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FR:SAN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 24, 2025	2025 (Q3)	2.84 / -	2.86	―	―	―
Jul 31, 2025	2025 (Q2)	1.64 / 1.59	1.73	-8.09% (-0.14)
Apr 24, 2025	2025 (Q1)	1.68 / 1.38	1.78	-22.47% (-0.40)
Jan 30, 2025	2024 (Q4)	1.35 / 1.31	1.66	-21.08% (-0.35)
Oct 25, 2024	2024 (Q3)	2.48 / 2.86	2.55	12.16% (+0.31)
Jul 25, 2024	2024 (Q2)	1.65 / 1.73	1.74	-0.57% (-0.01)
Apr 25, 2024	2024 (Q1)	1.73 / 1.78	2.16	-17.59% (-0.38)
Feb 01, 2024	2023 (Q4)	1.73 / 1.66	1.71	-2.92% (-0.05)
Oct 27, 2023	2023 (Q3)	2.60 / 2.55	2.88	-11.46% (-0.33)
Jul 28, 2023	2023 (Q2)	1.68 / 1.74	1.73	0.58% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FR:SAN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	€85.52	€78.84	-7.81%
Apr 24, 2025	€89.31	€89.41	+0.12%
Jan 30, 2025	€97.56	€99.25	+1.73%
Oct 25, 2024	€93.48	€95.86	+2.54%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Sanofi (FR:SAN) report earnings?

Sanofi (FR:SAN) is schdueled to report earning on Oct 24, 2025, Before Open (Confirmed).

What is Sanofi (FR:SAN) earnings time?

Sanofi (FR:SAN) earnings time is at Oct 24, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Sanofi stock?

The P/E ratio of Sanofi is N/A.

What is FR:SAN EPS forecast?

FR:SAN EPS forecast for the fiscal quarter 2025 (Q3) is 2.84.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing